James Hwang · Constituency Assistant, House of Commons
National Pharmaceutical Strategy as it relates to the federal government's involvement in federal/provincial access to medicines framework.Read more
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time to reimbursement and streamline federal/provincial listing processes.
Any and all free trade treaty agreements as it relates to the North American Free Trade Agreement (NAFTA) and trade negotiations between Canada as it relates to the European Union, India, Japan and the Trans-Pacific Partnership. International trade policies in support of the biopharmaceutical industry, including competitive and predictable intellectual property protection, product regulation and patient access to medicines.
Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations.
Pharmaceutical pricing policy issues arising from the jurisdiction of the Patended Medicines Prices Review Board (PMPRB) and R&D reporting.
Sony Perron · Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
and 6 moreShow fewer
Rodrigo Arancibia · Director, Innovation, Science and Economic Development Canada (ISED)
Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
Justine Frame · Policy Advisor, Health Canada (HC)
Linsey Hollett · Assistant Deputy Minister, Health Canada (HC)
Pharmaceutical pricing policy issues arising from the jurisdiction of the Patended Medicines Prices Review Board (PMPRB) and R&D reporting.Read more
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time to reimbursement and streamline federal/provincial listing processes.
Common Drug Review Policies as it relates to reimbursement recommendation decision-making process and framework.
Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations.
Any and all free trade treaty agreements as it relates to the North American Free Trade Agreement (NAFTA) and trade negotiations between Canada as it relates to the European Union, India, Japan and the Trans-Pacific Partnership. International trade policies in support of the biopharmaceutical industry, including competitive and predictable intellectual property protection, product regulation and patient access to medicines.
Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Rodrigo Arancibia · Director, Innovation, Science and Economic Development Canada (ISED)
Smart Regulations as it relates to the biopharmaceutical industry.Read more
Health Canada's Legislative and Regulatory Modernization (LRM) as it relates to the review, approval, transparency and compliance activities of biopharmaceutical products. Health Canada's Regulatory Roadmap for Health Products and Food as it relates to proposed policy and regulatory changes related to the review, approval, transparency and compliance activities of biopharmacuetical products.
National Pharmaceutical Strategy as it relates to the federal government's involvement in federal/provincial access to medicines framework.
Pharmaceutical pricing policy issues arising from the jurisdiction of the Patended Medicines Prices Review Board (PMPRB) and R&D reporting.
The government's Science and Technology strategy as it relates to the biopharmaceutical industry.
Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
Health Canada's Legislative and Regulatory Modernization (LRM) as it relates to the review, approval, transparency and compliance activities of biopharmaceutical products. Health Canada's Regulatory Roadmap for Health Products and Food as it relates to proposed policy and regulatory changes related to the review, approval, transparency and compliance activities of biopharmacuetical products.Read more
Smart Regulations as it relates to the biopharmaceutical industry.
National Pharmaceutical Strategy as it relates to the federal government's involvement in federal/provincial access to medicines framework.
Pharmaceutical pricing policy issues arising from the jurisdiction of the Patended Medicines Prices Review Board (PMPRB) and R&D reporting.
The government's Science and Technology strategy as it relates to the biopharmaceutical industry.
Justine Frame · Policy Advisor, Health Canada (HC)
Health Canada's Legislative and Regulatory Modernization (LRM) as it relates to the review, approval, transparency and compliance activities of biopharmaceutical products. Health Canada's Regulatory Roadmap for Health Products and Food as it relates to proposed policy and regulatory changes related to the review, approval, transparency and compliance activities of biopharmacuetical products.Read more
Smart Regulations as it relates to the biopharmaceutical industry.
National Pharmaceutical Strategy as it relates to the federal government's involvement in federal/provincial access to medicines framework.
Pharmaceutical pricing policy issues arising from the jurisdiction of the Patended Medicines Prices Review Board (PMPRB) and R&D reporting.
Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
Justine Frame · Special Assistant- Policy, Health Canada (HC)
Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
National Pharmaceutical Strategy as it relates to the federal government's involvement in federal/provincial access to medicines framework.Read more
Canada's Access to Medicines Regime with respect to ensuring that the program allows for the delivery of timely access to needed medicines to the developing world supported by a business climate in Canada that continues to encourage research into further treatment and prevention of disease.
Pharmaceutical pricing policy issues arising from the jurisdiction of the Patended Medicines Prices Review Board (PMPRB) and R&D reporting.
Establish accountability with the federally financed Canadian Agency for Drugs and Technologies in Health (CADTH).
US - Canada Regulatory Cooperation Council (RCC) as it relates to the regulation of biopharmaceutical products.
Patented Medicines (Notice of Compliance) Regulations with respect to ensuring that patent rights are respected and are internationally competitive.
Food and Drug Regulations as it relates to data protection and the regulation and protection of biopharmaceutical products.
Patented Medicines Regulations as it relates to the regulation and protection of biopharmaceutical products.
Annual federal Budgets and Budget updates as it relates to the biopharmaceutical industry, and related updates and to Federal budgetary policy.
Food and Drugs Act and Regulations and the Import and Export Permits Act with respect to cross-border trade as it relates to the export of Canadian biopharmaceuticals.
Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs) with respect to the protection of data, Access to Medicines, and TRIPs "flexibility". Merck is seeking to ensure Canada's continued compliance with its obligations under TRIPs relevant to the biopharmaceutical industry within all domestic legislation in addition to ongoing and future trade negotiations. Relevant domestic legislation includes the Food and Drugs Act, the Patent Act, and related regulations and guidance documents. Beyond TRIPs, Merck is seeking enhancements to increase the stability and global competitiveness of Canada’s intellectual Property legislation, regulations and policies relevant to the biopharmaceutical industry. Such enhancements may result from domestic policy in addition to bilateral and multilateral trade negotiations (e.g. Comprehensive Economic and Trade Agreement (CETA) and the Trans-Pacific Partnership (TPP).Read more
David K Lee · Chief Regulatory Officer, Health Canada (HC)
Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs) with respect to the protection of data, Access to Medicines, and TRIPs "flexibility". Merck is seeking to ensure Canada's continued compliance with its obligations under TRIPs relevant to the biopharmaceutical industry within all domestic legislation in addition to ongoing and future trade negotiations. Relevant domestic legislation includes the Food and Drugs Act, the Patent Act, and related regulations and guidance documents. Beyond TRIPs, Merck is seeking enhancements to increase the stability and global competitiveness of Canada’s intellectual Property legislation, regulations and policies relevant to the biopharmaceutical industry. Such enhancements may result from domestic policy in addition to bilateral and multilateral trade negotiations (e.g. Comprehensive Economic and Trade Agreement (CETA) and the Trans-Pacific Partnership (TPP).Read more
Martin Moen · Associate Asst Dep. Minister, Trade Policy and Negotiations, Global Affairs Canada (GAC)
Loris Mirella · Director - Intellectual Property Trade Policy, Global Affairs Canada (GAC)
Gabrielle Dolgoy · Acting Deputy Director, Global Affairs Canada (GAC)
David Norris · Senior Trade Policy Officer, Global Affairs Canada (GAC)
Any and all free trade treaty agreements as it relates to the North American Free Trade Agreement (NAFTA) and trade negotiations between Canada as it relates to the European Union, India, Japan and the Trans-Pacific Partnership. International trade policies in support of the biopharmaceutical industry, including competitive and predictable intellectual property protection, product regulation and patient access to medicines.Read more
Chase Knight · Parliamentary Secretary Assistant and Parliamentary Affairs Advisor, Innovation, Science and Economic Development Canada (ISED)
Lisa Xie · Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
Victoria Morton · Senior Communications Advisor, House of Commons
The government's Science and Technology strategy as it relates to the biopharmaceutical industry.Read more
Canada's Access to Medicines Regime with respect to ensuring that the program allows for the delivery of timely access to needed medicines to the developing world supported by a business climate in Canada that continues to encourage research into further treatment and prevention of disease.
Elizabeth Wong · Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
Canada's Access to Medicines Regime with respect to ensuring that the program allows for the delivery of timely access to needed medicines to the developing world supported by a business climate in Canada that continues to encourage research into further treatment and prevention of disease.Read more
The government's Science and Technology strategy as it relates to the biopharmaceutical industry.
Sandenga Yeba · Senior Policy Advisor, Health Canada (HC)
Justine Frame · Special Assistant- Policy, Health Canada (HC)
The government's Science and Technology strategy as it relates to the biopharmaceutical industry.Read more
Canada's Access to Medicines Regime with respect to ensuring that the program allows for the delivery of timely access to needed medicines to the developing world supported by a business climate in Canada that continues to encourage research into further treatment and prevention of disease.
ritu Banerjee · Assistant deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Greg Orencsak · Deputy Minister, Health Canada (HC)
Sarah Lawley · Assistant Deputy Minister, Health Canada (HC)
Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
Canada's Access to Medicines Regime with respect to ensuring that the program allows for the delivery of timely access to needed medicines to the developing world supported by a business climate in Canada that continues to encourage research into further treatment and prevention of disease.Read more
Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
Daniel MacDonald · Director General, Health Canada (HC)
Establish accountability with the federally financed Canadian Agency for Drugs and Technologies in Health (CADTH).Read more
Canada's Access to Medicines Regime with respect to ensuring that the program allows for the delivery of timely access to needed medicines to the developing world supported by a business climate in Canada that continues to encourage research into further treatment and prevention of disease.
Sandenga Yeba · Senior Policy Advisor, Health Canada (HC)
Shahad Khalladi · Senior Policy Advisor, Health Canada (HC)
Justine Frame · Special Assistant- Policy, Health Canada (HC)
US - Canada Regulatory Cooperation Council (RCC) as it relates to the regulation of biopharmaceutical products.Read more
Health Canada's Legislative and Regulatory Modernization (LRM) as it relates to the review, approval, transparency and compliance activities of biopharmaceutical products. Health Canada's Regulatory Roadmap for Health Products and Food as it relates to proposed policy and regulatory changes related to the review, approval, transparency and compliance activities of biopharmacuetical products.
David K Lee · Chief Regulatory Officer, Health Canada (HC)
Discussion focused on sharing perspectives on priorities and resourcing. In particular, a shared observation of an increase in submission reviews exceeding established timeframes and increasing challenges with securing pre-filing meetings were discussedRead more
Canada's Access to Medicines Regime with respect to ensuring that the program allows for the delivery of timely access to needed medicines to the developing world supported by a business climate in Canada that continues to encourage research into further treatment and prevention of disease.Read more
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026.
Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month.
Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means.
Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence.
PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.